Neoadjuvant m-vac (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder
- 15 September 1993
- Vol. 72 (6) , 1975-1982
- https://doi.org/10.1002/1097-0142(19930915)72:6<1975::aid-cncr2820720631>3.0.co;2-i
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder CancerJournal of Urology, 1992
- Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancerPublished by Springer Nature ,1992
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 1989
- Neo‐adjuvant Chemotherapy for Invasive Bladder Cancer. Experience with the M‐VAC RegimenBritish Journal of Urology, 1989
- Management of Invasive Bladder NeoplasmsPublished by Springer Nature ,1989
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Neoadjuvant Chemotherapy for Locally Advanced Transitional Cell Carcinoma of the Bladder: Do Local Findings Suggest a Potential for Salvage of the Bladder?Mayo Clinic Proceedings, 1988
- Combination Chemotherapy with Cisplatin and Methotrexate in Advanced Transitional Cell Cancer of the BladderJournal of Urology, 1987
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985